🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the register
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
2500 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
A Phase II, Randomized, Open-label, Multi-center Study of AK104 in Combination with Lenvatinib versus Lenvatinib in Participants with Advanced Hepatocellular Carcinoma Who Have Progressed on Atezolizumab and Bevacizumab
2025-524591-30-00Hepatocellular Carcinoma
Akeso Biopharma Co. Ltd.
Neoplasms
Poland, France, Spain, Italy
18/08/2026
Phase I
A study to test how well different and multiple doses of BI 3034701 are tolerated in people living with overweight or obesity
2026-526090-42-00overweight, obesity
Boehringer Ingelheim International GmbH
Nutritional and Metabolic Diseases
Germany
18/08/2026
Phase I
A clinical research study investigating how the body processes the new compound afabicin in people with kidney problems and people with normal kidney function
2026-526916-35-00Renal Impairment
Debiopharm International S.A.
Not possible to specify
Germany
18/08/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and when Coadministered with Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)
2025-525102-38-00Elevated lipoprotein(a)
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Netherlands, Denmark, Germany, Spain
18/08/2026
Phase II
A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by open-label extension in participants with early Alzheimer’s disease.
2025-524581-14-00Dementia Alzheimer's type
Sanofi-Aventis Recherche & Developpement
Nervous System Diseases
Spain, Germany
18/08/2026
Phase III
Evaluation of the efficacy of intravenous lidocaine on chronic postoperative pain in patients requiring emergency abdominal surgery. Randomized, double-blind, controlled, multicenter study – LIDOC-POPEYE.
2025-523682-24-00emergency abdominal surgery
Centre Hospitalier Universitaire De Nantes
Anesthesia and Analgesia
France
17/08/2026
Phase II
FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML
2025-523632-39-00acute myeloid lymphoma
Institut Paoli Calmettes
Neoplasms
France
17/08/2026
Phase III
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered via Intravitreal Injection in Participants with Neovascular Age-related Macular Degeneration
2025-523500-72-00Neovascular Age-related Macular Degeneration (nAMD)
Amgen Inc.
Eye Diseases
Slovakia, Latvia, Czechia, Poland, Spain, Hungary, Lithuania
17/08/2026
Phase II
Efficacy of rituximab for remission maintenance in patients with primary angiitis of the central nervous system: an open-label, randomized, controlled trial comparing systematic rituximab infusions and azathioprine - MAINRIPAC
2026-525394-39-00Patients with primary angiitis of the central nervous system
Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience
Nervous System Diseases
France
17/08/2026
Phase I
A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
2025-524080-20-00Metastatic castration resistant prostate cancer
Novartis Pharma AG
Neoplasms
France, Italy, Spain, Germany
17/08/2026
Phase III
Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)
2026-525513-31-00Small-cell lung cancer, limited stage
Norges Teknisk-Naturvitenskapelige Universitet NTNU
Neoplasms
Denmark, Finland, Estonia, Germany, Lithuania, Sweden, Norway, Netherlands
17/08/2026
Phase II
Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on Walking Ability in Patients in the Chronic Phase of Stroke
2025-521693-33-00Stroke
Sinfatin S.L.
Nervous System Diseases
Spain
17/08/2026
Phase III
C4931007 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
2025-523447-35-02Pneumoccoccal Immunisation
Pfizer Inc.
Bacterial Infections and Mycoses
Spain, Finland, Poland, Germany, Greece, Hungary, Italy
17/08/2026
Phase I/II
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)
2025-524915-36-00Lymphoma, Non-Hodgkin
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Germany, Spain, Finland, France
17/08/2026
Phase III
A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
2025-524445-27-00Metastatic castration-resistant prostate cancer (mCRPC)
BioNTech SE
Male Urogenital Diseases
Belgium, Spain, Italy, Poland, Germany, Hungary
17/08/2026
Phase I
A Two-part study to learn the amount of polymyxin E1 in the body over time formed after a single inhaled dose of colistimethate sodium (CMS) in healthy adults (Part 1) and after single inhaled and vein-infused doses of CMS in adults with non‑cystic fibrosis bronchiectasis (NCFB) (Part 2)
2025-524324-22-00Non-cystic fibrosis bronchiectasis
Zambon S.p.A.
Respiratory Tract Diseases
Belgium, Poland, Bulgaria
17/08/2026
Phase II
A phase IIa open-label dose-finding study with lead-in phase evaluating the safety, pharmacokinetics, and attenuating effects of trazodone on the consciousness-altering effects of psilocybin in individuals with Treatment-Resistant Depression
2025-523346-27-00Treatment-Resistant Depression
Universita' Degli Studi G. D'Annunzio Di Chieti
Mental Disorders
Italy
14/08/2026
Phase III
The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI
2026-525898-39-00Advanced hepatocellular carcinoma
Azienda Sanitaria Locale Napoli 1 Centro
Neoplasms
Italy
14/08/2026
Phase II
Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)
2026-526828-41-00Erosive hand osteoarthritis (EHOA)
Azienda Ospedaliera Universitaria Integrata Verona
Musculoskeletal Diseases
Italy
14/08/2026
Phase II
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)
2025-525033-31-00heart failure
Cardurion Pharmaceuticals Inc.
Cardiovascular Diseases
Latvia, Slovakia, Lithuania, Hungary, Italy, Netherlands, Spain, Poland, Bulgaria, Czechia
14/08/2026
Phase I
A study to test how BI 3034701 is taken up and processed by the body in healthy men with normal weight or overweight
2026-525825-19-00Healthy
Boehringer Ingelheim International GmbH
Not possible to specify
Hungary
14/08/2026
Phase I
Bioequivalence of Estradiol 10 mcg Vaginal Tablets in Healthy Women Participants.
2026-526477-42-00Not applicable (submitted trial is a bioavailability trial …
Laboratorios Leon Farma S.A.
Female Urogenital Diseases and Pregnancy Complications
Czechia
14/08/2026
Phase II
A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients with Severe Asthma not Adequately Controlled with Medium to High Dose ICS/LABA Therapy (PANAIRAMA)
2023-509125-41-00Severe asthma
Kinaset Therapeutics Inc.
Respiratory Tract Diseases
Czechia, Bulgaria, Romania, Hungary, Germany, Poland, Greece
14/08/2026
Phase II
An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer’s Disease
2026-525539-18-00Early Alzheimer’s Disease
Merry Life Biomedical Co. Ltd.
Nervous System Diseases
Sweden
14/08/2026
Phase I/II
An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases
2024-519491-60-00ANCA associated vasculitis (AAV), Immune thrombocytopenic p…
Universitaetsklinikum Tuebingen AöR
Immune System Diseases
Germany
14/08/2026
Rows per page Showing 201–225 of 2500
Previous 7 8 9 10 11 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.